PKF118-310

PKF118-310 is a **small molecule inhibitor** that disrupts the interaction between **transcription factor 4 (TCF4)** and **β-catenin**, thereby inhibiting canonical **Wnt/β-catenin signaling**[3][4][5]. It is also a **direct inhibitor of the lysine demethylase KDM4A (also known as JMJD2A)**, verified by in silico, in vitro, and cellular assays[1][7]. PKF118-310 shows **anticancer activity** in both liquid and solid tumor models, selectively inducing apoptosis and inhibiting cancer cell proliferation by modulating cell cycle and histone methylation marks (notably H3K9me3, H3K9me2, and H3K36me3 through KDM4A inhibition)[1][5]. It has also been used experimentally to suppress Wnt signaling in stem cell differentiation and tissue engineering contexts[2]. PKF118-310 is produced by Actinomycete strains and chemically known as toxoflavin[3][5]. Developer or manufacturer information is not formally disclosed but referenced in commercial catalogs.

Brand names

PKF118-310PKF-118-310PKF 118-310

Other names

toxoflavin